News & Stories

The Hong Kong University of Science and Technology (HKUST) showcased its groundbreaking advancements in medical technology and thought leadership at the 2025 Asia Summit on Global Health (ASGH) today.  As the event’s exclusive Thematic Session and Health Innovation Partner, HKUST highlighted how technology and collaboration can create a more equitable and sustainable healthcare system for hundreds of participants, including policymakers, healthcare experts, industry leaders, start-ups and investors from around the globe.  

The Hong Kong University of Science and Technology (HKUST) is receiving advisory support from Imperial College London (Imperial) and engaging with the University of California San Diego (UC San Diego) to pursue the establishment of the city’s third medical school, advancing medical education and clinical training. Echoing the government’s vision of building a third medical school that nurtures more doctors to meet the local demands and assists Hong Kong’s development into an international health and medical innovation hub, HKUST believes that new generations of doctors must possess the ability to serve and lead within the local context and leverage cutting-edge advancements in the global landscape of health and research. 

The Hong Kong University of Science and Technology (HKUST) has recently established strategic partnership with The First Affiliated Hospital of Sun Yat-sen University (FAH-SYSU), Southern Medical University (SMU), and Guangzhou Medical University (GMU) respectively. These individual partners will engage in in-depth collaboration with HKUST on areas such as clinical education, talent cultivation, medical research, and translation of innovations, injecting new impetus into the advancement of medical education and healthcare services.

The Hong Kong University of Science and Technology (HKUST) has signed a Memorandum of Understanding (MoU) with Microsoft Research Asia to enhance collaboration in medical health education and research. Focusing on three strategic areas – nurturing talent, revolutionizing smart healthcare, and developing enabling research – the MoU strives to drive the future collaboration of medical education through a holistic approach. According to the MoU, the two parties will use their respective strengths in research to foster exchange and collaboration in the medical health sector across three major areas. These include:

Structural biologists at The Hong Kong University of Science and Technology (HKUST) together with researchers at the AIDS Institute, The University of Hong Kong (HKU), Department of Microbiology, School of Clinical Medicine, the LKS Faculty of Medicine of The University of Hong Kong (HKUMed) and the State Key Laboratory of Emerging Infectious Diseases, HKU have demonstrated that ZCB11, a broadly neutralising antibody derived from a local mRNA-vaccinee against the spreading Omicron variants of SARS-CoV-2, displays potent antiviral activities against all variants of concern (VOCs), including the dominantly spreading Omicron BA.1, BA1.1 and BA.2. Critically, either prophylactic or therapeutic ZCB11 administration protects lung infection against Omicron viral challenge in golden Syrian hamsters.